Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction
NCT ID: NCT05446493
Last Updated: 2022-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2019-04-01
2022-01-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Daily Oral L-arginine Plus Tadalafil in Diabetic Patients With Erectile Dysfunction
NCT03834610
Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection
NCT00547183
Daily Tadalafil in Diabetic ED Patients
NCT06962462
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction
NCT05884957
Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction
NCT06583590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tadalafil group
Each patient will be treated by tadalafil 5mg daily for 3months
Tadalafil 5mg
* Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.
* Penile color Doppler ultrasound examination before and after treatment
control group
Estimation of serum YKL-40, platelet indices and serum total testosterone in healthy individuals in camparing with tadalafil group
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tadalafil 5mg
* Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.
* Penile color Doppler ultrasound examination before and after treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with major pelvic surgical intervention.
* Patients with hypogonadism and hyperprolactinemia.
* Patients with chronic liver disease.
* Patients with cardio vascular system diseases.
* History of chronic intake of central nervous system, anti androgen drugs or other drugs as Tramadol.
* Smokers patients.
* Patients with non-vasculogenic Erectile dysfunction.
30 Years
70 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aswan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Amer Ahmed Abdellatif
Assistant lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aswan university
Aswān, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
346/3/19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.